<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645203</url>
  </required_header>
  <id_info>
    <org_study_id>M01-352</org_study_id>
    <nct_id>NCT00645203</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media</brief_title>
  <official_title>An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of cefdinir oral suspension in children between 6 months
      and 4 years of age, with acute otitis media, who are at risk of persistent or recurrent
      otitis media.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteriological Response</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the otoscopic findings</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical exam; Vital signs; Use of concomitant medications</measure>
    <time_frame>59 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events assessment</measure>
    <time_frame>45 days with follow-up to a satisfactory conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory evaluations</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">447</enrollment>
  <condition>Acute Otitis Media</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefdinir</intervention_name>
    <description>cefdinir oral suspension, 25 mg/kg once daily for 10 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ABT-198, Omnicef, cefdinir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female children between 6 months and 4 years of age

          -  Weight does not exceed 40 kg

          -  Clinical diagnosis is acute otitis media

          -  Have evidence of middle ear fluid

          -  At risk for persistent or recurrent otitis media

          -  Generally in good health

        Exclusion Criteria:

          -  Sensitivity or allergy to penicillins or cephalosporins or inability to take oral
             medications

          -  Presence of tympanostomy tubes, ventilation tube or perforated tympanic membrane, in
             either ear

          -  Treatment with any anti-infective agent within 3 days prior to the study or treatment
             with a long-acting injectable antimicrobial agent (e.g. , penicillin G benzathine)
             within 4 weeks prior to the study

          -  Concomitant infection, that requires additional antimicrobial therapy

          -  Presence of a disease, complicating factor (e.g., mastoiditis), or structural
             abnormality that would preclude evaluation of the patient's therapeutic response
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clovis</city>
        <state>California</state>
        <zip>93611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Folsom</city>
        <state>California</state>
        <zip>95630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puente Alto, Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Uruca</city>
        <state>San Jose</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Domingo</city>
        <zip>ZC 02</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama</city>
        <zip>4087</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Costa Rica</country>
    <country>Dominican Republic</country>
    <country>Guatemala</country>
    <country>Israel</country>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>March 20, 2008</last_update_submitted>
  <last_update_submitted_qc>March 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Angela M Nilius, Ph.D.</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefdinir</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

